These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1202 related articles for article (PubMed ID: 22789917)
21. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management. Shustov A; Soma L Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216 [TBL] [Abstract][Full Text] [Related]
22. Fatal ALK-negative systemic anaplastic large cell lymphoma presenting with disseminated cutaneous dome-shaped papules and nodules. Bird JE; Leitenberger JJ; Solomon A; Blauvelt A; Hopkins S Dermatol Online J; 2012 May; 18(5):5. PubMed ID: 22630575 [TBL] [Abstract][Full Text] [Related]
23. Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project. Weisenburger DD; Anderson JR; Diebold J; Gascoyne RD; MacLennan KA; Müller-Hermelink HK; Nathwani BN; Ullrich F; Armitage JO Am J Hematol; 2001 Jul; 67(3):172-8. PubMed ID: 11391714 [TBL] [Abstract][Full Text] [Related]
24. ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity. Lazzeri D; Agostini T; Bocci G; Giannotti G; Fanelli G; Naccarato AG; Danesi R; Tuccori M; Pantaloni M; D'Aniello C Clin Breast Cancer; 2011 Oct; 11(5):283-96. PubMed ID: 21729665 [TBL] [Abstract][Full Text] [Related]
25. Treatment of Peripheral T-Cell Lymphoma: Many Shades of Gray. Lunning MA Oncology (Williston Park); 2015 Aug; 29(8):545-50. PubMed ID: 26281838 [TBL] [Abstract][Full Text] [Related]
26. Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases. Agrawal K; Shet T; Sridhar E; Dhende S; Sengar M; Arora B; Laskar S; Gujral S; Menon H; Banavali S Indian J Pathol Microbiol; 2017; 60(4):533-540. PubMed ID: 29323068 [TBL] [Abstract][Full Text] [Related]
27. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Niitsu N; Okamoto M; Nakamine H; Aoki S; Motomura S; Hirano M Hematol Oncol; 2008 Sep; 26(3):152-8. PubMed ID: 18395866 [TBL] [Abstract][Full Text] [Related]
28. [Efficacy of therapy of different variants of anaplastic large T-cell lymphomas]. Vinogradova IuE; Lutsenko IN; Kaplanskaia IB; Vorob'ev IA; Samoĭlova RS; Gorgidze LA; Ryzhikova NA; Valiev TT; Giliazitdinova EA; Dzhulakian UL; Egorova EK; Zvonkov EE; Krasil'nikova BB; Magomedova AU; Margolin OV; Mar'in DS; Kremenetskaia AM; Kravchenko SK; Vorob'ev AI Ter Arkh; 2008; 80(7):33-7. PubMed ID: 18763592 [TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma. Rassidakis GZ; Goy A; Medeiros LJ; Jiang Y; Thomaides A; Remache Y; Cabanillas F; Sarris AH; Gilles F Clin Cancer Res; 2003 Jun; 9(6):2213-20. PubMed ID: 12796388 [TBL] [Abstract][Full Text] [Related]
30. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. ten Berge RL; de Bruin PC; Oudejans JJ; Ossenkoppele GJ; van der Valk P; Meijer CJ Histopathology; 2003 Nov; 43(5):462-9. PubMed ID: 14636272 [TBL] [Abstract][Full Text] [Related]
32. Brentuximab vedotin in anaplastic large cell lymphoma. Skarbnik AP; Smith MR Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148 [TBL] [Abstract][Full Text] [Related]
33. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. Rassidakis GZ; Sarris AH; Herling M; Ford RJ; Cabanillas F; McDonnell TJ; Medeiros LJ Am J Pathol; 2001 Aug; 159(2):527-35. PubMed ID: 11485911 [TBL] [Abstract][Full Text] [Related]
34. ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase". Lu Y; Zhao X; Wang E; Chen W; Huang Q Leuk Res; 2010 Apr; 34(4):475-82. PubMed ID: 19695703 [TBL] [Abstract][Full Text] [Related]
35. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Savage KJ; Harris NL; Vose JM; Ullrich F; Jaffe ES; Connors JM; Rimsza L; Pileri SA; Chhanabhai M; Gascoyne RD; Armitage JO; Weisenburger DD; Blood; 2008 Jun; 111(12):5496-504. PubMed ID: 18385450 [TBL] [Abstract][Full Text] [Related]
36. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Jagasia M; Morgan D; Goodman S; Hamilton K; Kinney M; Shyr Y; Stein R; Zic J; Greer J Leuk Lymphoma; 2004 Nov; 45(11):2261-7. PubMed ID: 15512815 [TBL] [Abstract][Full Text] [Related]
37. [Clinical characteristics and prognostic factors of 40 cases of primary systemic anaplastic large cell lymphoma]. Chen YK; Yu WJ; Liu H; Wei JY; Qian WB; Jin J Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):222-227. PubMed ID: 32311892 [No Abstract] [Full Text] [Related]
38. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS; Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877 [TBL] [Abstract][Full Text] [Related]
39. Immunohistopathological features of anaplastic large-cell lymphoma according to anaplastic lymphoma kinase expression and bone marrow involvement pattern. Park SH; Chi HS; Cho YU; Jang S; Park CJ Histopathology; 2013 Jul; 63(1):13-8. PubMed ID: 23656317 [TBL] [Abstract][Full Text] [Related]
40. Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients. Wang YF; Yang YL; Gao ZF; Zhou CJ; Gregg X; Shi YF; Wang J; Yang XF; Ke XY J Hematol Oncol; 2012 Jul; 5():38. PubMed ID: 22769020 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]